Ault Milton C III's Form 4 filing
Alzamend Neuro, Inc. (ALZN) · filed Jul 29, 2025
- Accession no.
- 0001214659-25-011043
- Filed
- Jul 29, 2025
- Trade date
- Jul 25-28, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $128.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ault Milton C IIICIK 0001212502 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 25, 2025 | Common Stock | SSaleDisposed | −36,532 | $2.90F1 | −$105,942.8 | 46,020 | Indirect | |
| Jul 28, 2025 | Common Stock | SSaleDisposed | −8,311 | $2.68 | −$22,273.48 | 37,709 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $2.8976. The range of sales prices on the transaction date was $2.891 to $2.9129 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.
Referenced by the price of 1 transaction in Table I.